NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tahoe Therapeutics

Tahoe Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.tahoebio.ai/

Last Round

Series A

Aug 11, 2025

Est. Valuation

$120M

Total Funding Raised

$42.25M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Tahoe Therapeutics is a biotechnology company that develops AI-powered models of the human cell to facilitate the design of better drugs for patients, with an initial focus on cancer.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Synthetic Data

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Foundation

Keywords

drug discoverybiological foundation modelfoundation modelssingle-cell perturbationfrontier ai labvirtual cell modelsin vivo datasynthetic biologyai drug discoverydata as a serviceDaaSbiological datano-code analysisbiotech platformgenerative biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tahoe Therapeutics Comparables

Compare Tahoe Therapeutics with similar companies based on industry and business-model similarity.

Tahoe Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Transcripta Bio
82%
Gordian Biotechnology
82%
Noetik
80%

Tahoe Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 11, 2025
SeedDec 8, 2022

Key People

Founding team and executive leadership

Johnny Yu

Chief Scientific Officer and co-founder at Tahoe Therapeutics

Founding Team

Tahoe Therapeutics Investors

Notable investors and investment history

Tahoe Therapeutics investors
InvestorRounds
Camford CapitalSeed
Mubadala Capital VenturesSeries A
Conviction Investment PartnersSeries A
Venture HighwaySeries A, Seed
Mubadala CapitalSeries A, Seed
Wing Venture CapitalSeries A, Seed
Amplify PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Announced Tahoe-x1 for rapid ML model iteration.

  • Jan 1, 2026

    Launched Tahoe-100M, a large-scale single-cell dataset for training foundation models.

Tahoe Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tahoe Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tahoe Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range35
Year Founded2022
Last FundingAug 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.